Pons, MarionGeorgiadis, StylianosØstergaard, MikkelAhmadzay, Zohra FaizyGlintborg, BenteHeberg, JetteChristensen, Sara NysomRasmussen, Simon H.Loft, Anne GitteCastrejon, IsabelSánchez-Alonso, FernandoIannone, FlorenzoNordström, DanHokkanen, Anna-MariCiurea, AdrianNissen, Michael JZavada, JakubPavelka, KarelRotar, ZigaPirkmajer, Katja PerdanMichelsen, BrigitteMielnik, PawelBernardes, MiguelKhmelinskii, NikitaLaas, KarinVorobjov, SigridCodreanu, CatalinMacfarlane, Gary J.Jones, GarethGudbjornsson, BjornPalsson, OlafurWallman, Johan Kvan der Horst-Bruinsma, Irene EOnen, FatosHetland, Merete LundØrnbjerg, Lykke Midtbøll2025-01-272025-01-272025-05Pons, M, Georgiadis, S, Østergaard, M, Ahmadzay, Z F, Glintborg, B, Heberg, J, Christensen, S N, Rasmussen, S H, Loft, A G, Castrejon, I, Sánchez-Alonso, F, Iannone, F, Nordström, D, Hokkanen, A-M, Ciurea, A, Nissen, M J, Zavada, J, Pavelka, K, Rotar, Z, Pirkmajer, K P, Michelsen, B, Mielnik, P, Bernardes, M, Khmelinskii, N, Laas, K, Vorobjov, S, Codreanu, C, Macfarlane, G J, Jones, G, Gudbjornsson, B, Palsson, O, Wallman, J K, van der Horst-Bruinsma, I E, Onen, F, Hetland, M L & Ørnbjerg, L M 2025, 'Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis', Joint, Bone,Spine, vol. 92, no. 3, 105824. https://doi.org/10.1016/j.jbspin.2024.1058241297-319XORCID: /0000-0003-0016-7591/work/173415952https://hdl.handle.net/2164/24944On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG for supporting the EuroSpA collaboration. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit for publication.13988595engspondyloarthritisepidemiologybDMARDR Medicine (General)R1Journal article10.1016/j.jbspin.2024.105824923